-
New combination treatment offers significant benefits for people with recurring grade 3 astrocytoma
08 Dec 2025 12:51 GMT
… brain cancer, live longer.
Astrocytoma is an extremely challenging … brain tumor called anaplastic astrocytoma. But as medical definitions … grade 4 IDH-mutant astrocytoma.
Astrocytomas are primary brain tumors … in the treatment of astrocytoma, we move closer to …
-
<![CDATA[Eflornithine Plus Gleostine Improves Progression, Survival In Some With Astrocytoma]]>
23 Nov 2025 20:51 GMT
… grade 3 IDH-mutated astrocytoma, the addition of … #47;4, IDH-mutated astrocytoma.
Glossary
Progression-Free Survival … WHO grade 3 anaplastic astrocytoma. Patients were also … vs lomustine in recurrent anaplastic astrocytoma (AA) patients (STELLAR);” …
-
<![CDATA[Eflornithine Plus Lomustine Extends PFS, OS in Reclassified WHO Grade 3 IDH-Mutated Astrocytoma]]>
23 Nov 2025 07:24 GMT
… grade 3, IDH-mutated astrocytoma, according to updated data … criteria grade 3, IDH-mutated astrocytoma.
The HRs for PFS … 2021 grade 3 IDH-mutant astrocytoma. Presented at: 2025 SNO … vs lomustine in recurrent anaplastic astrocytoma (AA) patients (STELLAR). …
-
<![CDATA[Eflornithine/Lomustine Prolongs Survival in Recurrent mIDH Grade 3 Astrocytoma]]>
21 Nov 2025 19:21 GMT
… diagnosed patients with grade 3 astrocytoma. Full results will be presented … 343 adult patients with anaplastic astrocytoma (AA) whose disease has recurred … vs lomustine in recurrent anaplastic astrocytoma (AA) patients (STELLAR). ClinicalTrials.gov …
-
Astrocytoma Market Analysis and Growth Prospects 2025-2035 - Emerging Markets Set to Accelerate Astrocytoma Treatment Advancements Amid Rising Healthcare Access in Asia-Pacific - ResearchAndMarkets.com
13 Nov 2025 17:19 GMT
… and treatment.
Increasing prevalence of astrocytoma across varied demographics.
Government … StudiesAnalysis of recent breakthroughs in astrocytoma treatment protocols.
Industry Trends
… , especially for high-grade astrocytomas. Companies should also explore …
-
UK MHRA grants marketing authorization to vorasidenib to treat patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation
17 Sep 2025 03:57 GMT
… , known as grade 2 astrocytoma or oligodendroglioma with a susceptible … or radiotherapy following surgical intervention
Astrocytoma or oligodendroglioma with an?IDH … or IDH2-mutant grade 2 astrocytoma or oligodendroglioma. Patients receiving vorasidenib …
-
Rx Road Map: Vorasidenib for the Treatment of Astrocytoma/;Oligodendroglioma
07 Aug 2025 19:58 GMT
… and older with grade 2 astrocytoma or oligodendroglioma harboring a susceptible … approves vorasidenib for Grade 2 astrocytoma or oligodendroglioma with a susceptible … ;fda-approves-vorasidenib-grade-2-astrocytoma-or-oligodendroglioma-susceptible-idh1-or …
-
Advances in Treating Malignant Spinal Astrocytomas
04 Aug 2025 21:17 GMT
… in neuro-oncologychemotherapy for malignant astrocytomasimaging modalities in spinal surgeryimproving … oncologyintraoperative neurophysiological monitoringmalignant spinal cord astrocytomasmodern treatment strategies for spinal tumorsmultidisciplinary …
-
MB-101 Receives FDA Orphan Drug Designation for Astrocytoma and Glioblastoma
08 Jul 2025 19:48 GMT
… with recurrent diffuse and anaplastic astrocytoma and glioblastoma.1
“We are … recurrent glioblastoma and high-grade astrocytomas. Our novel therapeutic strategy, combining … CAR T-cells) to treat astrocytomas and glioblastoma. News release. July …
-
FDA Grants Orphan Drug Status to MB-101 for Glioblastoma, Astrocytomas
07 Jul 2025 22:19 GMT
… treatment of recurrent diffuse and astrocytomas (anaplastic astrocytoma) and glioblastoma (GBM), … recurrent GBM and high-grade astrocytomas.
Litchman continued, “This progress … recurrent glioblastoma and high-grade astrocytomas will depend on securing …